<?xml version="1.0" encoding="UTF-8"?><?xml-stylesheet type="text/xsl" href="http://www.visiongate3d.com/pinniped/wp-content/plugins/google-sitemap-generator/sitemap.xsl"?><!-- generator="wordpress/3.2.1" -->
<!-- sitemap-generator-url="http://www.arnebrachhold.de" sitemap-generator-version="3.2.4" -->
<!-- generated-on="January 23, 2012 5:23 pm" -->
<!-- Debug: Total comment count: 0 -->
<urlset xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.sitemaps.org/schemas/sitemap/0.9 http://www.sitemaps.org/schemas/sitemap/0.9/sitemap.xsd" xmlns="http://www.sitemaps.org/schemas/sitemap/0.9">	<url>
		<loc>http://www.visiongate3d.com/</loc>
		<lastmod>2012-01-23T17:22:19+00:00</lastmod>
		<changefreq>daily</changefreq>
		<priority>1.0</priority>
	</url>
<!-- Debug: Start Postings -->
<!-- Debug: Priority report of postID 870: Comments: 0 of 0 = 0 points -->
	<url>
		<loc>http://www.visiongate3d.com/medical-device-daily-visiongate-presents-at-onemedforum-2012-conference</loc>
		<lastmod>2012-01-23T17:22:19+00:00</lastmod>
		<changefreq>monthly</changefreq>
		<priority>0.2</priority>
	</url>
	<url>
		<loc>http://www.visiongate3d.com/about/management</loc>
		<lastmod>2012-01-23T17:05:10+00:00</lastmod>
		<changefreq>weekly</changefreq>
		<priority>0.6</priority>
	</url>
<!-- Debug: Priority report of postID 444: Comments: 0 of 0 = 0 points -->
	<url>
		<loc>http://www.visiongate3d.com/diagnostic-tests</loc>
		<lastmod>2012-01-16T16:45:10+00:00</lastmod>
		<changefreq>monthly</changefreq>
		<priority>0.2</priority>
	</url>
	<url>
		<loc>http://www.visiongate3d.com/newsroom</loc>
		<lastmod>2012-01-06T18:49:03+00:00</lastmod>
		<changefreq>weekly</changefreq>
		<priority>0.6</priority>
	</url>
<!-- Debug: Priority report of postID 855: Comments: 0 of 0 = 0 points -->
	<url>
		<loc>http://www.visiongate3d.com/visiongate-uses-2-6-million-nih-grant-to-achieve-full-automation-of-cell-ct%e2%84%a2-3d-imaging-system-for-early-diagnosis-of-cancer</loc>
		<lastmod>2012-01-06T18:38:36+00:00</lastmod>
		<changefreq>monthly</changefreq>
		<priority>0.2</priority>
	</url>
	<url>
		<loc>http://www.visiongate3d.com/newsroom/press-releases</loc>
		<lastmod>2012-01-06T18:37:36+00:00</lastmod>
		<changefreq>weekly</changefreq>
		<priority>0.6</priority>
	</url>
	<url>
		<loc>http://www.visiongate3d.com/careers</loc>
		<lastmod>2011-12-14T22:56:49+00:00</lastmod>
		<changefreq>weekly</changefreq>
		<priority>0.6</priority>
	</url>
<!-- Debug: Priority report of postID 822: Comments: 0 of 0 = 0 points -->
	<url>
		<loc>http://www.visiongate3d.com/visiongate-closes-2-million-financing-and-announces-collaboration-to-evaluate-its-3d-cell-imaging-platform-for-early-lung-cancer-detection</loc>
		<lastmod>2011-11-28T18:02:27+00:00</lastmod>
		<changefreq>monthly</changefreq>
		<priority>0.2</priority>
	</url>
<!-- Debug: Priority report of postID 840: Comments: 0 of 0 = 0 points -->
	<url>
		<loc>http://www.visiongate3d.com/visiongate-named-winner-of-arizona-governers-celebration-of-innovation-award-for-start-up-company-innovator-of-the-year</loc>
		<lastmod>2011-11-18T16:18:50+00:00</lastmod>
		<changefreq>monthly</changefreq>
		<priority>0.2</priority>
	</url>
	<url>
		<loc>http://www.visiongate3d.com/newsroom/in-the-news</loc>
		<lastmod>2011-10-19T19:44:30+00:00</lastmod>
		<changefreq>weekly</changefreq>
		<priority>0.6</priority>
	</url>
	<url>
		<loc>http://www.visiongate3d.com/investors/visiongate-at-a-glance</loc>
		<lastmod>2011-06-16T20:52:47+00:00</lastmod>
		<changefreq>weekly</changefreq>
		<priority>0.6</priority>
	</url>
	<url>
		<loc>http://www.visiongate3d.com/investors</loc>
		<lastmod>2011-06-16T20:51:47+00:00</lastmod>
		<changefreq>weekly</changefreq>
		<priority>0.6</priority>
	</url>
	<url>
		<loc>http://www.visiongate3d.com/cell-ct/intellectual-property</loc>
		<lastmod>2011-06-16T20:51:21+00:00</lastmod>
		<changefreq>weekly</changefreq>
		<priority>0.6</priority>
	</url>
	<url>
		<loc>http://www.visiongate3d.com/cell-ct/cellct-platform</loc>
		<lastmod>2011-06-16T20:50:32+00:00</lastmod>
		<changefreq>weekly</changefreq>
		<priority>0.6</priority>
	</url>
	<url>
		<loc>http://www.visiongate3d.com/cell-ct</loc>
		<lastmod>2011-06-16T20:50:10+00:00</lastmod>
		<changefreq>weekly</changefreq>
		<priority>0.6</priority>
	</url>
	<url>
		<loc>http://www.visiongate3d.com/about/strategic-partners</loc>
		<lastmod>2011-06-16T20:49:41+00:00</lastmod>
		<changefreq>weekly</changefreq>
		<priority>0.6</priority>
	</url>
	<url>
		<loc>http://www.visiongate3d.com/about</loc>
		<lastmod>2011-06-16T20:47:38+00:00</lastmod>
		<changefreq>weekly</changefreq>
		<priority>0.6</priority>
	</url>
<!-- Debug: Priority report of postID 242: Comments: 0 of 0 = 0 points -->
	<url>
		<loc>http://www.visiongate3d.com/the-city-of-phoenix-in-partnership-with-visiongate-inc-is-opening-the-world%e2%80%99s-first-biomedical-3d-cellular-imaging-lab</loc>
		<lastmod>2011-06-16T20:44:28+00:00</lastmod>
		<changefreq>monthly</changefreq>
		<priority>0.2</priority>
	</url>
<!-- Debug: Priority report of postID 240: Comments: 0 of 0 = 0 points -->
	<url>
		<loc>http://www.visiongate3d.com/visiongate-was-awarded-a-coveted-research-and-development-tax-grant</loc>
		<lastmod>2011-06-16T20:43:51+00:00</lastmod>
		<changefreq>monthly</changefreq>
		<priority>0.2</priority>
	</url>
<!-- Debug: Priority report of postID 98: Comments: 0 of 0 = 0 points -->
	<url>
		<loc>http://www.visiongate3d.com/practitioners</loc>
		<lastmod>2011-06-16T20:43:39+00:00</lastmod>
		<changefreq>monthly</changefreq>
		<priority>0.2</priority>
	</url>
<!-- Debug: Priority report of postID 103: Comments: 0 of 0 = 0 points -->
	<url>
		<loc>http://www.visiongate3d.com/healthcare-facilities</loc>
		<lastmod>2011-06-16T20:43:05+00:00</lastmod>
		<changefreq>monthly</changefreq>
		<priority>0.2</priority>
	</url>
<!-- Debug: Priority report of postID 105: Comments: 0 of 0 = 0 points -->
	<url>
		<loc>http://www.visiongate3d.com/patients</loc>
		<lastmod>2011-06-16T20:42:28+00:00</lastmod>
		<changefreq>monthly</changefreq>
		<priority>0.2</priority>
	</url>
<!-- Debug: Priority report of postID 255: Comments: 0 of 0 = 0 points -->
	<url>
		<loc>http://www.visiongate3d.com/swedish-cancer-institute-taking-part-in-development-of-cell-ct%e2%84%a2-platform-for-lung-cancer-risk-assessment</loc>
		<lastmod>2011-06-16T20:42:11+00:00</lastmod>
		<changefreq>monthly</changefreq>
		<priority>0.2</priority>
	</url>
<!-- Debug: Priority report of postID 253: Comments: 0 of 0 = 0 points -->
	<url>
		<loc>http://www.visiongate3d.com/peer-reviewed-publication-in-pattern-recognition-demonstrates-superiority-of-visiongate%e2%80%99s-cell-ct%e2%84%a2-patented-3d-cell-imaging-platform</loc>
		<lastmod>2011-06-16T20:40:53+00:00</lastmod>
		<changefreq>monthly</changefreq>
		<priority>0.2</priority>
	</url>
<!-- Debug: Priority report of postID 251: Comments: 0 of 0 = 0 points -->
	<url>
		<loc>http://www.visiongate3d.com/visiongate-and-seattle-cancer-care-alliance-join-forces-to-explore-new-technology-for-evaluating-lung-cancer-risk</loc>
		<lastmod>2011-06-16T20:39:58+00:00</lastmod>
		<changefreq>monthly</changefreq>
		<priority>0.2</priority>
	</url>
<!-- Debug: Priority report of postID 248: Comments: 0 of 0 = 0 points -->
	<url>
		<loc>http://www.visiongate3d.com/arizona-state-university%e2%80%99s-biodesign-institute-will-acquire-the-first-commercially-available-cell-ct%e2%84%a2-imaging-platform-from-visiongate-inc</loc>
		<lastmod>2011-06-16T20:39:12+00:00</lastmod>
		<changefreq>monthly</changefreq>
		<priority>0.2</priority>
	</url>
<!-- Debug: Priority report of postID 230: Comments: 0 of 0 = 0 points -->
	<url>
		<loc>http://www.visiongate3d.com/worlds-first-biomedical-cell-ct%e2%84%a2-research-lab-to-open</loc>
		<lastmod>2011-06-16T20:38:21+00:00</lastmod>
		<changefreq>monthly</changefreq>
		<priority>0.2</priority>
	</url>
<!-- Debug: Priority report of postID 232: Comments: 0 of 0 = 0 points -->
	<url>
		<loc>http://www.visiongate3d.com/visiongate-receives-3-million-in-government-grants</loc>
		<lastmod>2011-06-16T20:37:45+00:00</lastmod>
		<changefreq>monthly</changefreq>
		<priority>0.2</priority>
	</url>
<!-- Debug: Priority report of postID 246: Comments: 0 of 0 = 0 points -->
	<url>
		<loc>http://www.visiongate3d.com/visiongate-inc-today-announced-that-it-presented-five-abstracts-describing-its-cell-ct-system-for-3d-cellular-imaging</loc>
		<lastmod>2011-06-16T20:37:35+00:00</lastmod>
		<changefreq>monthly</changefreq>
		<priority>0.2</priority>
	</url>
<!-- Debug: Priority report of postID 235: Comments: 0 of 0 = 0 points -->
	<url>
		<loc>http://www.visiongate3d.com/visiongate-presented-a-summary-of-the-luced-test-development-at-the-24th-international-conference-for-lung-cancer-screening-held-in-scottsdale-arizona</loc>
		<lastmod>2011-06-16T20:36:05+00:00</lastmod>
		<changefreq>monthly</changefreq>
		<priority>0.2</priority>
	</url>
<!-- Debug: Priority report of postID 571: Comments: 0 of 0 = 0 points -->
	<url>
		<loc>http://www.visiongate3d.com/columnar-cell</loc>
		<lastmod>2011-06-16T20:34:51+00:00</lastmod>
		<changefreq>monthly</changefreq>
		<priority>0.2</priority>
	</url>
<!-- Debug: Priority report of postID 567: Comments: 0 of 0 = 0 points -->
	<url>
		<loc>http://www.visiongate3d.com/cell-ct</loc>
		<lastmod>2011-06-16T20:34:44+00:00</lastmod>
		<changefreq>monthly</changefreq>
		<priority>0.2</priority>
	</url>
<!-- Debug: Priority report of postID 530: Comments: 0 of 0 = 0 points -->
	<url>
		<loc>http://www.visiongate3d.com/welcome-to-visiongate</loc>
		<lastmod>2011-06-16T00:03:29+00:00</lastmod>
		<changefreq>monthly</changefreq>
		<priority>0.2</priority>
	</url>
<!-- Debug: Priority report of postID 569: Comments: 0 of 0 = 0 points -->
	<url>
		<loc>http://www.visiongate3d.com/adenocarcinoma</loc>
		<lastmod>2011-06-15T23:50:58+00:00</lastmod>
		<changefreq>monthly</changefreq>
		<priority>0.2</priority>
	</url>
	<url>
		<loc>http://www.visiongate3d.com/terms</loc>
		<lastmod>2011-06-15T23:19:22+00:00</lastmod>
		<changefreq>weekly</changefreq>
		<priority>0.6</priority>
	</url>
	<url>
		<loc>http://www.visiongate3d.com/about/strategic-advisors</loc>
		<lastmod>2011-06-15T21:55:07+00:00</lastmod>
		<changefreq>weekly</changefreq>
		<priority>0.6</priority>
	</url>
	<url>
		<loc>http://www.visiongate3d.com/about/medical-advisory-board</loc>
		<lastmod>2011-06-15T21:50:35+00:00</lastmod>
		<changefreq>weekly</changefreq>
		<priority>0.6</priority>
	</url>
	<url>
		<loc>http://www.visiongate3d.com/newsroom/publications</loc>
		<lastmod>2011-06-15T21:46:32+00:00</lastmod>
		<changefreq>weekly</changefreq>
		<priority>0.6</priority>
	</url>
	<url>
		<loc>http://www.visiongate3d.com/investors/faq</loc>
		<lastmod>2011-05-16T16:36:37+00:00</lastmod>
		<changefreq>weekly</changefreq>
		<priority>0.6</priority>
	</url>
	<url>
		<loc>http://www.visiongate3d.com/newsroom/events</loc>
		<lastmod>2011-05-03T19:31:46+00:00</lastmod>
		<changefreq>weekly</changefreq>
		<priority>0.6</priority>
	</url>
	<url>
		<loc>http://www.visiongate3d.com/about/contact</loc>
		<lastmod>2011-04-12T18:10:45+00:00</lastmod>
		<changefreq>weekly</changefreq>
		<priority>0.6</priority>
	</url>
	<url>
		<loc>http://www.visiongate3d.com/blog</loc>
		<lastmod>2011-03-28T20:30:22+00:00</lastmod>
		<changefreq>weekly</changefreq>
		<priority>0.6</priority>
	</url>
<!-- Debug: End Postings -->
<!-- Debug: Start Custom Pages -->
<!-- Debug: End Custom Pages -->
<!-- Debug: Start additional URLs -->
<!-- Debug: End additional URLs -->
</urlset>
